Organogenesis Holdings (ORGO) Aktievy
Organogenesis Holdings Inc. är ett bolag inom regenerativ medicin som utvecklar, tillverkar och kommersialiserar produkter för avancerad sårvård, kirurgi och sportmedicin i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 4/6 |
| Framtida tillväxt | 0/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
ORGO Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Organogenesis Holdings Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$2.55 |
| 52 veckors högsta | US$7.08 |
| 52 veckors lägsta | US$2.04 |
| Beta | 1.33 |
| 1 månads förändring | 4.94% |
| 3 månaders förändring | 6.25% |
| 1 års förändring | -49.20% |
| 3 års förändring | -40.28% |
| 5 års förändring | -82.65% |
| Förändring sedan börsintroduktionen | -81.03% |
Senaste nyheter och uppdateringar
Recent updates
ORGO: Reimbursement Reset And Knee OA BLA Will Support Future Upside
Analysts have kept their $3 price target on Organogenesis Holdings intact, citing the view that reimbursement changes and a potential shakeout among smaller competitors could eventually help the company, while recently lowered guidance and limited near term revenue upside restrain expectations. What's in the News Organogenesis Holdings issued earnings guidance for the first half, second half, and full year 2026, indicating total net revenue in a range of $270.0 million to $310.0 million compared with $564.2 million reported for full year 2025, based on company guidance.Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked
Summary Organogenesis is grappling with significant revenue declines in 2026 due to adverse Medicare policy changes impacting its core skin substitute products. 2025 marked a peak year for ORGO, but 2026 guidance now calls for a 45–52% year-over-year revenue drop to $270–310 million. Market headwinds have intensified, with clinicians in some cases moving away from skin substitutes entirely, compounding ORGO's challenges. Management anticipates a gradual turnaround through 2026, with a potential acceleration in Q4. ReNu, its knee injection with a novel MOA and blockbuster potential, is awaiting FDA approval of its pending BLA. Read the full article on Seeking AlphaORGO: Reimbursement Shakeout And Knee Osteoarthritis BLA Will Drive Future Upside
Analysts reduced their price target on Organogenesis Holdings to $3, citing reimbursement-driven structural shifts that could eventually benefit the company as smaller competitors exit. They also pointed to limited near-term revenue upside after management lowered guidance to reflect a steeper expected decline in 2026.
ORGO: FDA Rolling BLA For Knee Osteoarthritis Will Support Bullish Outlook
Analysts have maintained their $8.00 price target on Organogenesis Holdings, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E that they view as better aligned with the company’s current risk and earnings profile. What's in the News Organogenesis completed a planned Type B meeting with the FDA, securing confirmation to begin a rolling Biologics License Application for ReNu, with the filing expected to start before the end of December (Key Developments).ORGO: FDA BLA Progress For Knee Osteoarthritis Will Support Bullish Outlook
Analysts have slightly trimmed their price targets on Organogenesis Holdings, citing updated assumptions that include a modestly higher discount rate, slightly stronger revenue growth and profit margin estimates, and a somewhat lower future P/E multiple. What's in the News Organogenesis Holdings reported a successful Type B meeting with the FDA that cleared the way to start a rolling Biologics License Application, or BLA, for its ReNu product, with filing planned before the end of December (Key Developments).ORGO: FDA Rolling Submission For Knee Osteoarthritis Therapy Will Support Bullish Outlook
Analysts have nudged their price target on Organogenesis Holdings higher to US$8.00, citing slightly firmer assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News Completed a planned Type B meeting with the FDA, receiving confirmation to initiate a rolling Biologics License Application for ReNu, targeted before the end of December (Key Developments).The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Revenues Yet As Shares Tumble 28%
Organogenesis Holdings Inc. ( NASDAQ:ORGO ) shareholders won't be pleased to see that the share price has had a very...Is Organogenesis Holdings (NASDAQ:ORGO) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...ORGO: Regulatory Momentum For Knee Osteoarthritis Therapy Will Support Bullish Outlook
Analysts have raised their fair value estimate for Organogenesis Holdings from US$7.00 to US$8.00, citing changes in the discount rate, revenue growth assumptions, profit margin expectations and future P/E estimates as key drivers of the updated price target. What's in the News Completed a planned Type-B meeting with the FDA, with confirmation to begin a rolling Biologics License Application (BLA) for ReNu before the end of December (Key Developments).ORGO: Upcoming Knee Osteoarthritis BLA Filing Will Drive Long Term Upside
Analysts have modestly lifted their price target on Organogenesis Holdings to 8.50 dollars from 8.50 dollars, reflecting slightly higher long term profitability and valuation assumptions despite essentially unchanged growth and fair value estimates. What's in the News Completed a planned Type B FDA meeting confirming the path to initiate a rolling Biologics License Application for ReNu for knee osteoarthritis before the end of December, which advances the regulatory strategy for this lead asset (Key Developments) Raised 2025 guidance and projected net product revenue between 500.0 million dollars and 525.0 million dollars, an increase of 4% to 9% year over year, with expected net income between 8.6 million dollars and 25.4 million dollars (Key Developments) Reported that the second Phase 3 randomized controlled trial of ReNu in knee osteoarthritis did not meet its primary endpoint for statistical significance, but showed numerical pain reduction improvements and maintained a favorable safety profile, supporting plans for an FDA BLA filing (Key Developments) Highlighted that ReNu has been evaluated in three large randomized controlled trials involving more than 1,300 patients and previously received FDA Regenerative Medicine Advanced Therapy designation for knee osteoarthritis, which reinforces its clinical and regulatory foundation (Key Developments) Valuation Changes Fair Value Estimate remained unchanged at 8.50 dollars per share, indicating a stable view of intrinsic equity value.ORGO: Upcoming Knee Osteoarthritis FDA Filing Will Support Future Share Price Expansion
Analysts have modestly raised their price target on Organogenesis Holdings to 8.50 dollars from 7.50 dollars, citing a slightly higher assumed future price to earnings multiple that more than offsets minor adjustments to the discount rate and margin assumptions. What's in the News Raised 2025 earnings guidance, expecting net product revenue of 500 million to 525 million dollars, up 4% to 9% year over year from 482 million dollars in 2024, with projected net income between 8.6 million and 25.4 million dollars (company guidance).Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Shares Bounce 27% But Its Business Still Trails The Industry
Organogenesis Holdings Inc. ( NASDAQ:ORGO ) shares have had a really impressive month, gaining 27% after a shaky period...ORGO: Anticipated 2025 Guidance And Promising Data Will Support Share Price Expansion
Analysts have revised their price target for Organogenesis Holdings downward from $8.00 to $7.50. This reflects a tempered outlook based on updated forecasts for revenue growth and profit margins.CMS Reform And Capacity Expansion Will Unlock Long Term Value
With no change in key metrics such as Future P/E and Net Profit Margin, the consensus analyst price target for Organogenesis Holdings remains steady at $8.00. What's in the News Organogenesis updated full-year 2025 guidance: expects net product revenue between $480 million and $510 million (roughly flat to 6% growth) and net income (loss) ranging from a $6.4 million loss to a $16.4 million profit.Organogenesis Holdings Inc. (NASDAQ:ORGO) Stock Catapults 36% Though Its Price And Business Still Lag The Industry
Despite an already strong run, Organogenesis Holdings Inc. ( NASDAQ:ORGO ) shares have been powering on, with a gain of...
LCD Delays And ReNu Progress Will Unlock Market Potential
Delay in LCDs implementation offers a chance to capitalize on demand, boosting near-term revenue and market share for key products.There's No Escaping Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Muted Revenues Despite A 69% Share Price Rise
The Organogenesis Holdings Inc. ( NASDAQ:ORGO ) share price has done very well over the last month, posting an...Organogenesis: Lurking Disruption With Recovery To Follow
Summary Medicare reimbursement issues expected for certain of Organogenesis' skin substitute projects disrupting revenues in 2025. Major catalyst is expected for ORGO with BLA filing in late 2025. Liquidity is adequate and excellent potential for acquisition on expected pullbacks. Read the full article on Seeking AlphaWhy Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S
Organogenesis Holdings Inc.'s ( NASDAQ:ORGO ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong...We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope
Key Insights Organogenesis Holdings to hold its Annual General Meeting on 20th of June Salary of US$908.7k is part of...Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst
Summary Organogenesis has two disproportionate segments, with Surgical and Sports Medicine making up a small portion of revenues. The company's pipeline candidate, ReNu, has the potential to boost Surgical and Sports Medicine revenues. In recent years, Organogenesis has generated inconsistent earnings and may not need to raise cash before launching ReNu. Read the full article on Seeking AlphaInvestors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality
Organogenesis Holdings Inc.'s ( NASDAQ:ORGO ) recent soft profit numbers didn't appear to worry shareholders, as the...Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Aktieägarnas avkastning
| ORGO | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | -3.0% | 0.09% | -0.7% |
| 1Y | -49.2% | 31.4% | 15.3% |
Avkastning vs industri: ORGO presterade sämre än US Biotechs branschen som gav 31.4 % under det senaste året.
Avkastning vs Marknaden: ORGO presterade sämre än US marknaden som gav 15.3 % under det senaste året.
Prisvolatilitet
| ORGO volatility | |
|---|---|
| ORGO Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: ORGO har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: ORGO s veckovolatilitet ( 9% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| n/a | 854 | Gary Gillheeney | organogenesis.com |
Organogenesis Holdings Inc. är ett bolag inom regenerativ medicin som utvecklar, tillverkar och kommersialiserar produkter för avancerad sårvård, kirurgi och sportmedicin i USA. Bolagets produkter för avancerad sårvård omfattar Affinity och Novachor, som är placentaallograft från amnion och chorion för användning vid behandling av kroniska och akuta sår som skyddande barriärer och ECM-ställningar (extracellulär matris); Apligraf, ett bioteknologiskt hudsubstitut i två lager för behandling av venösa bensår och diabetesfotsår; Dermagraft, ett hudsubstitut som odlas från mänskliga dermala fibroblaster för behandling av diabetesfotsår; NuShield, ett uttorkat allograft av placenta och en kirurgisk barriär som ger en skyddande barriär och ECM-ställning för att stödja naturlig läkning; PuraPly Antimicrobial (AM) och PuraPly SX, som är antimikrobiella barriärer för behandling av öppna sår i kirurgiska miljöer; och CYGNUS Dual, VIA Matrix och SimpliMax är vävnadstransplantat av placenta som används för att behandla kroniska och akuta sår och som kan förvaras i rumstemperatur. Företaget tillhandahåller också PuraPly MZ, en mikroniserad version av PuraPly för behandling av öppna sår i kirurgiska miljöer; PuraForce, en bioteknisk kirurgisk matris av porcint kollagen för användning vid förstärkning av mjukvävnad; FortiShield, en biosyntetisk sårmatris för användning som ett tillfälligt skyddande hölje; och TransCyte, en bioteknisk vävnadsställning som främjar läkning av brännskador.
Organogenesis Holdings Inc. Sammanfattning av grunderna
| ORGO grundläggande statistik | |
|---|---|
| Börsvärde | US$307.53m |
| Vinst(TTM) | -US$14.55m |
| Intäkter(TTM) | US$514.70m |
Är ORGO övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| ORGO resultaträkning (TTM) | |
|---|---|
| Intäkter | US$514.70m |
| Kostnad för intäkter | US$134.39m |
| Bruttovinst | US$380.31m |
| Övriga kostnader | US$394.86m |
| Intäkter | -US$14.55m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
Aug 06, 2026
| Vinst per aktie (EPS) | -0.11 |
| Bruttomarginal | 73.89% |
| Nettovinstmarginal | -2.83% |
| Skuld/egenkapitalförhållande | 0% |
Hur har ORGO utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/27 05:09 |
| Aktiekurs vid dagens slut | 2026/07/27 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Organogenesis Holdings Inc. bevakas av 8 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Michael Gorman | BTIG |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Richard Newitter | Leerink Partners LLC |